Latest news
Debiopharm Group™ and TCG Lifesciences Ltd. enter into an exclusive research agreement to develop a novel class of antibiotics, a…
Go To Market Consulting Inc. and Debiopharm Group™ collaborate to identify early stage in-licensing opportunities on the US West Coast
KeyLemon secures Series A Investment co-led by Debiopharm Investment and Swisscom ventures
Debiopharm Group™ initiates phase I dose escalation study with Debio 1347 (CH5183284) in advanced solid tumors with FGFR alterations
Debiopharm Group™ presents the ‘Debiopharm Group Life Sciences Award 2013’ and two ‘Junior Debiopharm Group Life Sciences Awards 2013’ during…
Alacrita and Debiopharm Group™ collaborate to identify early stage drug candidates from the Massachusetts life science cluster
Aurigene and Debiopharm Group™ report nomination of development candidate Debio 0617B in oncology